-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, La4eaau9zClegHzLAzOyMraW4SebVwyndSyOW//gilHQixiwvC+/cyx9DbBsv0W+ GejsgZ42nVn94VgmuoXFDg== 0001127602-10-005194.txt : 20100217 0001127602-10-005194.hdr.sgml : 20100217 20100217180617 ACCESSION NUMBER: 0001127602-10-005194 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100215 FILED AS OF DATE: 20100217 DATE AS OF CHANGE: 20100217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tragash Steven Alan CENTRAL INDEX KEY: 0001462532 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30111 FILM NUMBER: 10614183 MAIL ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LEXICON PHARMACEUTICALS, INC./DE CENTRAL INDEX KEY: 0001062822 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 760474169 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 BUSINESS PHONE: 2818633000 MAIL ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON GENETICS INC/TX DATE OF NAME CHANGE: 20000126 4 1 form4.xml PRIMARY DOCUMENT X0303 4 2010-02-15 0001062822 LEXICON PHARMACEUTICALS, INC./DE LXRX 0001462532 Tragash Steven Alan 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381 1 VP, Corporate Affairs Stock Option (Right to Buy) 1.90 2010-02-15 4 A 0 75000 0 A 2020-02-15 Common Stock 75000 75000 D Restricted Stock Units (Phantom Stock) 2010-02-15 4 A 0 10500 0 A Common Stock 10500 10500 D Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/15/2011) and vests 1/48th per month for each month of service thereafter. Each restricted stock unit represents a contingent right to receive one share of common stock. Restricted stock units vest with respect to 100% of the shares subject to the restricted stock unit upon the dosing of the first patient in a pivotal human clinical trial in any country, the results of which could be used to establish safety and efficacy of a pharmaceutical product discovered or developed by the Company (whether or not licensed by the Company to a third party) as a basis for a New Drug Application with the U.S. Food and Drug Administration or that would otherwise satisfy the requirements of 21 CFR 321.21(c) or its foreign equivalent. /s/ Steven A. Tragash 2010-02-17 -----END PRIVACY-ENHANCED MESSAGE-----